P. Jane McDowell

Jun 20, 2024 | erj.ersjournals.com | O'Byrne PM |Godard PP |P. Jane McDowell |Ron McDowell

To the Editor:We read with interest the editorial “Clinical remission with biologic therapies in severe asthma: a matter of definition” [1]. We absolutely agree that the definition of clinical remission is of critical importance, and as with rheumatology, gastroenterology and dermatology, this is likely to be an iterative process.

Dec 14, 2023 | erj.ersjournals.com | P. Jane McDowell |Ron McDowell |John Busby |M. Chad Eastwood

IntroductionAsthma is a heterogenous disease of the airways characterised by variable airways hyperresponsiveness and chronic inflammation. It is estimated that 5–10% of asthmatic patients have “severe asthma”, defined by the European Respiratory Society (ERS)/American Thoracic Society (ATS) as “asthma which requires treatment with Global Initiative for Asthma (GINA) step 4–5 treatment or oral corticosteroids (OCS) for 50% of the last year to prevent it becoming uncontrolled” (see ) [1, 2].

Oct 19, 2023 | erj.ersjournals.com | P. Jane McDowell |Ron McDowell |John Busby |M. Chad Eastwood

FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.